Exploring the Mechanism of Plaque Rupture in Acute Coronary Syndrome Using Coronary CT Angiography and Computational Fluid Dynamics II (EMERALD II) Study

Summary

The EMERALD II study is a multinational, multicenter, and retrospective study. ACS patients who underwent CCTA from 1 months to 3 years prior to the event will be retrospectively identified. Plaques in the non-culprit vessels will be regarded as a primary control group.

Conditions

• Acute Myocardial Infarction
• Unstable Angina

Interventions

DIAGNOSTIC_TEST

Coronary CT angiography

Comprehensive CCTA analysis of all culprit and non-culprit lesions to obtain their per-lesion and per-vessel quantitative, qualitative plaque, and hemodynamic features is performed by the independent core laboratory (HeartFlow, Mountain View, CA, USA) blinded to patient characteristics and ICA findings. The current CCTA reporting variables, including % diameter stenosis, segment involvement score (SIS), and HRP features, are obtained for all lesions by another independent core laboratory (University of British Columbia, Vancouver, Canada) to construct a reference model. ICA and invasive imaging studies performed at the event of ACS are analyzed by the independent core laboratory (Samsung Medical Center, Seoul, Korea) to define the culprit lesion blinded to CCTA findings. Other independent experts match culprit and non-culprit lesion data between ICA and CCTA findings.

Sponsors & Collaborators

• Inje University Ilsan Paik Hospital

  collaborator OTHER

• St. Mary's hostpital

  collaborator UNKNOWN

• Odense University Hospital

  collaborator OTHER

• University of Milan

  collaborator OTHER

• Imperial College London

  collaborator OTHER

• Aarhus University Hospital

  collaborator OTHER

• Semmelweis University

  collaborator OTHER

• Oxford University Hospitals NHS Trust

  collaborator OTHER

• Emory University

  collaborator OTHER

• Ehime University Graduate School of Medicine

  collaborator OTHER

• Gifu Heart Center

  collaborator OTHER

• Wakayama Medical University

  collaborator OTHER

• Keimyung University Dongsan Medical Center

  collaborator OTHER

• Seoul National University Bundang Hospital

  collaborator OTHER

• Seoul National University Hospital Healthcare System Gangnam Center

  collaborator UNKNOWN

• Chosun University Hospital

  collaborator OTHER

• Chungnam National University Hospital

  collaborator OTHER

• Monzino Cardiology Center

  collaborator UNKNOWN

• OLV Hospital

  collaborator UNKNOWN

• Monash Heart

  collaborator UNKNOWN

• University of British Columbia

  collaborator OTHER

• MOUNT SINAI HOSPITAL

  collaborator OTHER

• Tokyo Medical University Hachioji Medical Center

  collaborator UNKNOWN

• Tokai University

  collaborator OTHER

• St. Luke's International Hospital

  collaborator UNKNOWN

• Aichi Medical University

  collaborator OTHER

• Toyohashi Heart Center

  collaborator OTHER

• Kobe University Hospital

  collaborator UNKNOWN

• National Cerebral and Cardiovascular Center, Japan

  collaborator OTHER

• Shin Koga Hospital

  collaborator UNKNOWN

• Saiseikai Kumamoto Hospital

  collaborator UNKNOWN

• Tsuchiura Kyodo Hospital

  collaborator UNKNOWN

• Tokyo Medical Dental University

  collaborator UNKNOWN

• Loyola University

  collaborator OTHER

• Leiden University

  collaborator OTHER

• Weil Cornell Medical College

  collaborator UNKNOWN

• West Penn Allegheny Health System

  collaborator OTHER

• Ulsan Hospital

  collaborator UNKNOWN

• Ulsan University Hospital

  collaborator OTHER

• Seoul National University Hospital

  lead OTHER

Principal Investigators

• Bon-Kwon Koo, MD,PhD · Seoul National University Hospital

Eligibility

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2018-07-09

Primary Completion

2022-09-30

Completion

2022-12-31

Countries

• South Korea

Study Locations